Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]-Resminostat in Healthy Males
NCT04955340Phase 1Completed
- Sponsor
- 4SC AG
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Resminostat in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by 4SC AG. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration, Area under the concentration-time curve from time zero to infinity and 7 more. Started Oct 2021; status: completed.
02
Drugs
Resminostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT04955340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955340.